Prostate Cancer
Conditions
Keywords
Prostate Cancer, Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Hypofractionated Radiotherapy, Pelvic Lymph Node Irradiation
Brief summary
This phase II randomized controlled study aims to compare the treatment results of intermediate and high risk prostate cancer patients treated with hormonal therapy and radical radiotherapy with or without pelvic lymph nodes in NCI- Cairo University.
Detailed description
Study Design : Phase II prospective randomized trial with 2 arms • Prostate Only (Arm A) Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to dose of 60Gy/20fractions (3 Gy per fraction) • Prostate & Pelvic Lymph Nodes (Arm B) Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to dose of 60Gy/20fractions (3 Gy per fraction)
Interventions
RADIATIONProstate Only Radiation
Prostate Only Radiation for Intermediate and High Risk Prostate cancer
RADIATIONProstate and Pelvic Lymph Node Radiation
Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase II prospective randomized trial with 2 arms: * Prostate Only (Arm A) o Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to dose of 60Gy/20fractions (3 Gy per fraction) * Prostate & Pelvic Lymph Nodes (Arm B) * Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to dose of 60Gy/20fractions (3 Gy per fraction)
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Histologically-proven prostatic adenocarcinoma. * Risk stratification from intermediate to very high risk will be included according to NCCN guide lines September 5, 2019 version 4.2019: * Intermediate risk: T2b or T2c and/or GS =7 and/or PSA \>10-20. Both the favorable intermediate (1 intermediate risk factor (IRF) and Grade Group 1 or 2 and \<50% biopsy core positive) and unfavorable intermediate risk (2 or 3 IRFs and/or Grade Group 3 and/or ≥50% biopsy cores positive) will be included. * High risk: T3a or PSA \>20 or Grade Group 4 or 5, not very high risk. * Very high risk: T3b-4, primary gleason pattern 5 OR \>4 cores with grade group 4 or 5 * N stage: N0 * M Stage: M0 * Performance Status: PS 0-2
Exclusion criteria
* Low risk prostate cancer * Histologies other than adenocarcinoma * Patients with significant comorbidities might affect treatment completion and follow up * Previously received pelvic radiotherapy * Patients with metastatic disease * Poor performance status (PS ≥ 3)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute toxicity | 90 days post the end of radiation therapy | Compare Acute toxicity between the 2 arms using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. |
| Local Control | 1 year | Compare Local control (LC) with minimum follow up of 1 year in both groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical free survivals (BFS) | 1 year | Biochemical free survivals (BFS) with minimum follow up of 1 year in both groups. |
| Late toxicity | 1 year | Compare Late toxicity (using RTOG/EORTC Late Radiation Toxicity Scale) |
| Overall survival (OS) | 1 year | Compare overall survival in the study population |
Countries
Egypt
Contacts
Primary ContactAhmed Abdelhamid, Msc
Outcome results
None listed